Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
February 17, 2020

Epizyme seeks FDA accelerated approval for Tazverik to treat follicular lymphoma

Epizyme is seeking accelerated approval from the US Food and Drug Administration (FDA) for its Tazverik (tazemetostat) to treat patients with relapsed or refractory follicular lymphoma (FL).

The US FDA’s Center for Drug Evaluation and Research. (Credit: The U.S. Food and Drug Administration)